EHA 2022 | Dose-escalation and expansion study of ivosidenib in patients with IDH1-mutant MDS
David Sallman, MD, Moffit Cancer Center, Tampa, FL, shares the results of the dose-escalation and expansion study of ivosidenib in patients with IDH1-mutant myelodysplastic syndromes (MDS) (NCT02074839). Overall, the study reported that ivosidenib was effective and well-tolerated, with many patients achieving durable complete remissions. The results of this study may lead to the approval of ivosidenib in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Incyte: Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Agios: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy.
